Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439551 · ClinicalTrials.gov registry record
Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)
A clinical trial, sponsored by MeMed Diagnostics.
- Completed
- Registry status
- 215
- Enrollment target
NCT05439551: Completed study, sponsored by MeMed Diagnostics.
NCT05439551 is a clinical trial that has completed, run by MeMed Diagnostics. The registered enrollment target is 215 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439551 has completed, sponsored by MeMed Diagnostics.
- COMPLETED
- Registry status
- 215 participants
- Enrollment target
Study Summary
This is a Prospective, multi-center, sample collection study enrolling pediatric and adult subjects presented to the ED/Urgent care, with symptoms consistent with acute bacterial or viral infection will be recruited according to eligibility criteria. The study is designed to measure the MeMed BV®️ score in whole blood and serum samples and demonstrate the equivalence between the two matrices. Patients will be managed according to the current standard of care per standard institutional procedures.
Interventions
- DIAGNOSTIC_TEST MeMed BV®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2023-09-29 |
What the finished NCT05439551 record still lists
NCT05439551 is an observational study that tracks outcomes without assigning an intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which MeMed BV® is the first listed.
NCT05439551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05439551 about?
NCT05439551 is a clinical study titled "Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)". This is a Prospective, multi-center, sample collection study enrolling pediatric and adult subjects presented to the ED/Urgent care, with symptoms consistent with acute bacterial or viral infection will be recruited according to eligibility criteria. The study is designed to measure the MeMed BV®️ s...
What is the current status of trial NCT05439551?
This trial is currently completed. The enrollment target is 215 participants. The study started on 2022-02-11. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT05439551?
The interventions under investigation include: MeMed BV® (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05439551?
This trial is sponsored by MeMed Diagnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI